← Back to patent-cliff list
Cefazolin (B Braun Medical)
Tier C — Watch / tradeCefazolin (B Braun Medical)
-
Originator
2000
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PBPs
Indications (approved)：胆道疾病, 附睾炎, Respiratory tract infection, Urinary tract infection, Sepsis, Skin and skin structure infection, 前列腺炎, 手术伤口感染
Regional status
US
Approved
2000-07-27
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Cefazolin (B Braun Medical)?
Approved indications include: 胆道疾病, 附睾炎, Respiratory tract infection, Urinary tract infection, Sepsis, Skin and skin structure infection, 前列腺炎, 手术伤口感染.
When does the Cefazolin (B Braun Medical) patent expire?
No public expiry year is available for Cefazolin (B Braun Medical) yet; this page updates once verified.
How do I get a quote for Cefazolin (B Braun Medical) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27